Introduktion
Den här sidan ger en omfattande analys av den kända insiderhandelshistoriken för Jeffrey W Sherman. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. Det är olagligt för insiders att göra affärer i sina företag baserat på specifik, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4. Trots dessa restriktioner tyder akademisk forskning på att insiders – i allmänhet – tenderar att överträffa marknaden i sina egna företag.
Genomsnittlig handelslönsamhet
Den genomsnittliga handelslönsamheten är den genomsnittliga avkastningen av alla köp på den öppna marknaden som insidern gjort under de senaste tre åren. För att beräkna detta undersöker vi alla oplanerade köp på öppen marknad som görs av insidern, exklusive alla affärer som markerats som en del av en 10b5-1-handelsplan. Vi beräknar sedan den genomsnittliga prestandan för dessa affärer under 3, 6 och 12 månader, med ett genomsnitt av var och en av dessa varaktigheter för att generera ett slutgiltigt resultatmått för varje affär. Slutligen tar vi ett genomsnitt av alla prestationsmått för att beräkna ett prestationsmått för insidern. Denna lista inkluderar endast insiders som har gjort minst tre affärer under de senaste två åren.
Om lönsamheten för denna insiderhandel är "N/A", så har insidern antingen inte gjort några köp på den öppna marknaden under de senaste tre åren, eller så är affärerna de har gjort för nya för att kunna beräkna ett tillförlitligt resultatmått.
Uppdateringsfrekvens: Dagligen
Företag med rapporterade insiderpositioner
SEC-anmälningarna visar att Jeffrey W Sherman har rapporterat innehav eller affärer i följande företag:
Värdepapper | Titel | Senaste rapporterade innehav |
---|---|---|
US:XERS / Xeris Biopharma Holdings, Inc. | Director | 219 188 |
US:HZNP / Horizon Therapeutics Plc | EVP and Chief Medical Officer | 0 |
US:SBBP / Strongbridge Biopharma plc | Director | 0 |
Director | 0 |
Hur man tolkar diagrammen
Följande diagram visar aktieutvecklingen för värdepapper efter varje icke-planerad handel på öppen marknad som görs av Jeffrey W Sherman. Icke-planerad handel är affärer som inte gjordes som en del av en 10b5-1-handelsplan. Aktieutvecklingen visas som kumulativ procentuell förändring av aktiekursen. Till exempel, om en insiderhandel gjordes den 1 januari 2019, kommer diagrammet att visa den dagliga procentuella förändringen av värdepapperet fram till idag. Om aktiekursen skulle gå från $10 till $15 under denna tid, skulle den kumulativa procentuella förändringen i aktiekursen vara 50%. En förändring i priset från 10 USD till 20 USD skulle vara 100 % och en prisändring på 10 USD till 5 USD skulle vara -50 %.
I slutändan försöker vi avgöra hur nära insiders affärer korrelerar med överavkastning (positiv eller negativ) i aktiekursen för att se om insidern tar tid för sina affärer att dra nytta av insiderinformation. Tänk på situationen där en insider gjorde detta. I den här situationen förväntar vi oss antingen (a) positiv avkastning efter köp eller (b) negativ avkastning efter försäljning. I fallet med (a) skulle KÖP-diagrammet visa en serie uppåtlutande kurvor, vilket indikerar positiv avkastning efter varje köptransaktion. I fallet med (b) skulle SALE-diagrammet visa en serie nedåtlutande kurvor, vilket indikerar negativ avkastning efter varje försäljningstransaktion.
Detta är dock inte tillräckligt för att dra slutsatser. Om till exempel aktiekursen i bolaget var i en icke-cyklisk stigning under många år, skulle vi förvänta oss att alla tomter efter köpet skulle vara uppåtlutande. Likaså skulle icke-cykliska nedgångar under många år resultera i nedåtlutande post-trade tomter. Inget av dessa diagram skulle tyda på insiderhandel.
Den starkaste indikatorn skulle vara en situation där aktiekursen var extremt cyklisk, och det fanns både positiva signaler i KÖP-diagrammet och negativa plotter på SALE-diagrammet. Denna situation skulle i hög grad tyda på en insider som tog tid för affärer till sin ekonomiska fördel.
Insiderköp XERS / Xeris Biopharma Holdings, Inc. - Analys av kortsiktig vinst
I det här avsnittet analyserar vi lönsamheten för varje oplanerat insiderköp på en öppen marknad som görs i XERS / Xeris Biopharma Holdings, Inc.. Denna analys hjälper till att förstå om insidern konsekvent genererar onormal avkastning och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste öppna marknadsköpen som inte var en del av en automatisk handelsplan.
Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till max |
Pris vid max |
Max vinst ($) |
Maximal avkastning (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2023-11-27 | XERS | SHERMAN JEFFREY W | 5 400 | 1,8700 | 5 400 | 1,8700 | 10 098 | 347 | 3.4700 | 8 640 | 85,56 |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderförsäljning - Analys av kortsiktig förlust
I det här avsnittet analyserar vi det kortsiktiga undvikandet av förluster för varje oplanerad insiderförsäljning på öppen marknad som görs i XERS / Xeris Biopharma Holdings, Inc.. Ett konsekvent mönster för att undvika förluster kan tyda på att framtida försäljningstransaktioner kan förutsäga prisnedgångar. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Följande tabell visar de senaste försäljningarna på den öppna marknaden som inte ingick i en automatisk handelsplan.
Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till min |
Pris vid min |
Maximal förlust undvikits ($) |
Maximal förlust undvikits ($) |
---|---|---|---|---|---|---|---|---|---|---|---|
2025-08-28 | XERS | SHERMAN JEFFREY W | 42 232 | 7,9209 | 42 232 | 7,9209 | 334 515 | 18 | 7.3600 | −23 687 | −7,08 |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderhandelshistorik
Den här tabellen visar den fullständiga listan över insideraffärer gjorda av Jeffrey W Sherman som avslöjats för Securities Exchange Commission (SEC).
Fildatum | Transaktionsdatum | Schema | Ticker | Värdepapper | Kode | Aktier | Återstående aktier | Procentuell förandring | Aktie pris |
Transaktionsvärde | Återstående värde |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2025-08-29 |
|
4 | XERS |
Xeris Biopharma Holdings, Inc.
Common Stock |
S - Sale | −42 232 | 219 188 | −16,15 | 7,92 | −334 515 | 1 736 166 | |
2025-08-29 |
|
4 | XERS |
Xeris Biopharma Holdings, Inc.
Common Stock |
M - Exercise | 47 040 | 261 420 | 21,94 | 6,66 | 313 286 | 1 741 057 | |
2025-06-04 |
|
4 | XERS |
Xeris Biopharma Holdings, Inc.
Common Stock |
A - Award | 50 000 | 214 380 | 30,42 | ||||
2024-06-05 |
|
4 | XERS |
Xeris Biopharma Holdings, Inc.
Common Stock |
A - Award | 50 000 | 164 380 | 43,71 | ||||
2024-04-11 |
|
4 | XERS |
Xeris Biopharma Holdings, Inc.
Common Stock |
J - Other | 6 502 | 114 380 | 6,03 | ||||
2023-11-29 |
|
4 | XERS |
Xeris Biopharma Holdings, Inc.
Common Stock |
P - Purchase | 5 400 | 5 400 | 1,87 | 10 098 | 10 098 | ||
2023-10-06 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
D - Sale to Issuer | −45 352 | 0 | −100,00 | 116,50 | −5 283 508 | ||
2023-10-06 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
D - Sale to Issuer | −80 944 | 0 | −100,00 | 116,50 | −9 429 976 | ||
2023-10-06 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
D - Sale to Issuer | −105 808 | 0 | −100,00 | 116,50 | −12 326 632 | ||
2023-10-06 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
D - Sale to Issuer | −2 655 | 0 | −100,00 | 116,50 | −309 308 | ||
2023-09-07 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
G - Gift | −2 165 | 80 944 | −2,61 | ||||
2023-06-07 |
|
4 | XERS |
Xeris Biopharma Holdings, Inc.
Common Stock |
A - Award | 42 500 | 107 878 | 65,01 | ||||
2023-01-18 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
G - Gift | 33 795 | 83 109 | 68,53 | ||||
2023-01-18 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
G - Gift | −33 795 | 2 376 | −93,43 | ||||
2023-01-12 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
S - Sale | X | −3 368 | 36 171 | −8,52 | 113,10 | −380 921 | 4 090 940 |
2023-01-12 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
S - Sale | X | −3 368 | 39 539 | −7,85 | 113,05 | −380 752 | 4 469 884 |
2023-01-06 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
S - Sale | X | −5 187 | 49 314 | −9,52 | 113,29 | −587 635 | 5 586 783 |
2023-01-06 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
F - Taxes | −22 655 | 42 907 | −34,56 | 113,24 | −2 565 452 | 4 858 789 | |
2023-01-06 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
M - Exercise | 51 132 | 65 562 | 354,35 | ||||
2023-01-04 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
F - Taxes | −9 717 | 14 430 | −40,24 | 113,80 | −1 105 795 | 1 642 134 | |
2023-01-04 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
M - Exercise | 21 772 | 24 147 | 916,72 | ||||
2022-12-13 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
S - Sale | X | −21 378 | 84 430 | −20,20 | 111,45 | −2 382 484 | 9 409 352 |
2022-12-13 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
S - Sale | X | −6 974 | 54 501 | −11,34 | 111,44 | −777 208 | 6 073 788 |
2022-12-13 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
G - Gift | 8 531 | 61 475 | 16,11 | ||||
2022-12-13 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
G - Gift | −8 531 | 2 375 | −78,22 | ||||
2022-06-09 |
|
4 | XERS |
Xeris Biopharma Holdings, Inc.
Common Stock |
A - Award | 15 000 | 65 378 | 29,77 | ||||
2022-04-08 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
S - Sale | X | −42 009 | 10 629 | −79,81 | 110,02 | −4 621 872 | 1 169 413 |
2022-03-21 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Stock Option (Right to Buy) |
M - Exercise | −8 531 | 164 469 | −4,93 | ||||
2022-03-21 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
M - Exercise | 8 531 | 52 638 | 19,34 | 22,14 | 188 876 | 1 165 405 | |
2022-03-21 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
G - Gift | 8 169 | 52 944 | 18,24 | ||||
2022-03-21 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
G - Gift | −8 169 | 44 107 | −15,63 | ||||
2022-03-21 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
G - Gift | 5 287 | 52 276 | 11,25 | ||||
2022-03-21 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
G - Gift | −5 287 | 44 775 | −10,56 | ||||
2022-03-21 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
G - Gift | 12 304 | 50 062 | 32,59 | ||||
2022-03-21 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
G - Gift | −12 304 | 46 989 | −20,75 | ||||
2022-01-24 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Restricted Stock Units (RSUs) |
M - Exercise | −5 354 | 0 | −100,00 | ||||
2022-01-24 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
F - Taxes | −2 372 | 59 293 | −3,85 | 86,42 | −204 988 | 5 124 101 | |
2022-01-24 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
M - Exercise | 5 354 | 61 665 | 9,51 | ||||
2022-01-06 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Restricted Stock Units (RSU) |
M - Exercise | −9 314 | 18 628 | −33,33 | ||||
2022-01-06 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Restricted Stock Units (RSU) |
M - Exercise | −9 678 | 4 834 | −66,69 | ||||
2022-01-06 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Restricted Stock Units (RSU) |
M - Exercise | −9 222 | 9 223 | −50,00 | ||||
2022-01-06 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Restricted Stock Units (RSU) |
M - Exercise | −12 095 | 12 095 | −50,00 | ||||
2022-01-06 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Restricted Stock Units (RSU) |
M - Exercise | −12 261 | 0 | −100,00 | ||||
2022-01-06 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
F - Taxes | −37 675 | 56 311 | −40,09 | ||||
2022-01-06 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
A - Award | 32 301 | 93 986 | 52,36 | ||||
2022-01-06 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
M - Exercise | 52 570 | 61 685 | 576,74 | ||||
2022-01-06 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Restricted Stock Units (RSU) |
A - Award | 19 044 | 19 044 | |||||
2022-01-06 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
G - Gift | −50 | 37 758 | −0,13 | ||||
2022-01-06 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
G - Gift | 10 729 | 37 808 | 39,62 | ||||
2022-01-06 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
G - Gift | −10 729 | 9 115 | −54,07 | ||||
2021-10-29 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Stock Option (Right to Buy) |
M - Exercise | −10 729 | 0 | −100,00 | ||||
2021-10-29 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
M - Exercise | 10 729 | 19 844 | 117,71 | 7,61 | 81 648 | 151 013 | |
2021-10-06 |
|
4 | SBBP |
Strongbridge Biopharma plc
Stock Option (Right to Buy) |
D - Sale to Issuer | −140 000 | 0 | −100,00 | ||||
2021-10-06 |
|
4 | SBBP |
Strongbridge Biopharma plc
Ordinary Shares |
D - Sale to Issuer | −64 258 | 0 | −100,00 | ||||
2021-10-05 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | −11 228 | 0 | −100,00 | ||||
2021-10-05 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | −11 228 | 0 | −100,00 | ||||
2021-10-05 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | −20 000 | 0 | −100,00 | ||||
2021-10-05 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Stock Option (Right to Buy) |
D - Sale to Issuer | −19 650 | 0 | −100,00 | ||||
2021-10-05 |
|
4 | SBBP |
Strongbridge Biopharma plc
Ordinary Shares |
F - Taxes | −17 763 | 64 258 | −21,66 | 2,06 | −36 592 | 132 371 | |
2021-10-05 |
|
4 | XERS |
Xeris Biopharma Holdings, Inc.
Stock Option (Right to Buy) |
A - Award | 11 228 | 11 228 | |||||
2021-10-05 |
|
4 | XERS |
Xeris Biopharma Holdings, Inc.
Stock Option (Right to Buy) |
A - Award | 11 228 | 11 228 | |||||
2021-10-05 |
|
4 | XERS |
Xeris Biopharma Holdings, Inc.
Stock Option (Right to Buy) |
A - Award | 20 000 | 20 000 | |||||
2021-10-05 |
|
4 | XERS |
Xeris Biopharma Holdings, Inc.
Stock Option (Right to Buy) |
A - Award | 19 650 | 19 650 | |||||
2021-10-05 |
|
4 | XERS |
Xeris Biopharma Holdings, Inc.
Stock Option (Right to Buy) |
A - Award | 31 360 | 31 360 | |||||
2021-10-05 |
|
4 | XERS |
Xeris Biopharma Holdings, Inc.
Stock Option (Right to Buy) |
A - Award | 31 360 | 31 360 | |||||
2021-10-05 |
|
4 | XERS |
Xeris Biopharma Holdings, Inc.
Stock Option (Right to Buy) |
A - Award | 47 040 | 47 040 | |||||
2021-10-05 |
|
4 | XERS |
Xeris Biopharma Holdings, Inc.
Common Stock |
A - Award | 50 378 | 50 378 | |||||
2021-09-23 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Stock Option (Right to Buy) |
M - Exercise | −46 271 | 10 729 | −81,18 | ||||
2021-09-23 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
S - Sale | X | −46 271 | 9 115 | −83,54 | 110,00 | −5 089 810 | 1 002 650 |
2021-09-23 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
M - Exercise | 46 271 | 55 386 | 507,64 | 7,61 | 352 122 | 421 487 | |
2021-09-23 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
G - Gift | 4 042 | 27 079 | 17,55 | ||||
2021-09-23 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
G - Gift | −4 042 | 9 115 | −30,72 | ||||
2021-07-30 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Performance Restricted Stock Units (PSUs) |
A - Award | 14 514 | 14 514 | |||||
2021-07-30 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
F - Taxes | −3 215 | 13 157 | −19,64 | 102,50 | −329 538 | 1 348 592 | |
2021-07-30 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
A - Award | 7 257 | 16 372 | 79,62 | ||||
2021-07-02 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
S - Sale | X | −54 789 | 128 845 | −29,84 | 95,00 | −5 205 097 | 12 240 610 |
2021-07-02 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
S - Sale | X | −5 287 | 9 115 | −36,71 | 95,00 | −502 265 | 865 925 |
2021-07-02 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
G - Gift | 66 730 | 66 730 | |||||
2021-07-02 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
G - Gift | −66 730 | 14 402 | −82,25 | ||||
2021-06-08 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Stock Option (Right to Buy) |
A - Award | 11 228 | 11 228 | |||||
2021-05-18 |
|
4 | SBBP |
Strongbridge Biopharma plc
Ordinary Shares |
A - Award | 40 000 | 82 021 | 95,19 | ||||
2021-05-17 |
|
4 | SBBP |
Strongbridge Biopharma plc
Ordinary Shares |
F - Taxes | −18 944 | 42 021 | −31,07 | 2,35 | −44 518 | 98 749 | |
2021-02-19 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Performance Restricted Stock Units (PSUs) |
A - Award | 14 512 | 14 512 | |||||
2021-02-19 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Performance Restricted Stock Units (PSUs) |
A - Award | 3 931 | 3 931 | |||||
2021-02-19 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
F - Taxes | −871 | 80 083 | −1,08 | 87,17 | −75 925 | 6 980 835 | |
2021-02-19 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
A - Award | 1 965 | 80 954 | 2,49 | ||||
2021-01-22 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Performance Restricted Stock Units (PSUs) |
M - Exercise | −5 353 | 5 354 | −50,00 | ||||
2021-01-22 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
F - Taxes | −2 372 | 78 989 | −2,92 | 77,43 | −183 664 | 6 116 118 | |
2021-01-22 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
M - Exercise | 5 353 | 81 361 | 7,04 | ||||
2021-01-22 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
G - Gift | 8 679 | 183 634 | 4,96 | ||||
2021-01-22 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
G - Gift | −8 679 | 76 008 | −10,25 | ||||
2021-01-06 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Restricted Stock Units (RSU) |
M - Exercise | −12 094 | 24 190 | −33,33 | ||||
2021-01-06 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Restricted Stock Units (RSU) |
M - Exercise | −17 260 | 0 | −100,00 | ||||
2021-01-06 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Restricted Stock Units (RSU) |
M - Exercise | −12 261 | 12 261 | −50,00 | ||||
2021-01-06 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
F - Taxes | −45 256 | 84 687 | −34,83 | 73,28 | −3 316 360 | 6 205 863 | |
2021-01-06 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
A - Award | 60 313 | 129 943 | 86,62 | ||||
2021-01-06 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
M - Exercise | 41 615 | 69 630 | 148,55 | ||||
2021-01-06 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Restricted Stock Units (RSU) |
A - Award | 27 942 | 27 942 | |||||
2020-12-09 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
S - Sale | X | −31 133 | 174 955 | −15,11 | 71,32 | −2 220 406 | 12 477 791 |
2020-12-09 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
S - Sale | X | −9 631 | 206 088 | −4,46 | 70,60 | −679 949 | 14 549 813 |
2020-12-09 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
S - Sale | X | −10 489 | 215 719 | −4,64 | 72,24 | −757 725 | 15 583 541 |
2020-12-09 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
S - Sale | X | −16 200 | 226 208 | −6,68 | 71,52 | −1 158 624 | 16 178 396 |
2020-12-09 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
S - Sale | X | −36 389 | 242 408 | −13,05 | 70,31 | −2 558 511 | 17 043 706 |
2020-10-22 |
|
4/A | HZNP |
Horizon Therapeutics Public Ltd Co
Stock option (right to buy) |
M - Exercise | −13 000 | 57 000 | −18,57 | ||||
2020-10-22 |
|
4/A | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
M - Exercise | 13 000 | 28 015 | 86,58 | 7,61 | 98 930 | 213 194 | |
2020-10-21 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Stock option (right to buy) |
M - Exercise | −13 000 | 57 000 | −18,57 | ||||
2020-10-21 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
M - Exercise | 13 000 | 28 015 | 86,58 | 7,61 | 98 930 | 213 194 | |
2020-07-07 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
S - Sale | X | −9 100 | 278 797 | −3,16 | 57,50 | −523 250 | 16 030 828 |
2020-06-04 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Stock Option (right to buy) |
A - Award | 11 228 | 11 228 | |||||
2020-05-18 |
|
4 | SBBP |
Strongbridge Biopharma plc
Ordinary Shares |
F - Taxes | −19 035 | 60 965 | −23,79 | 2,86 | −54 440 | 174 360 | |
2020-05-15 |
|
4 | SBBP |
Strongbridge Biopharma plc
Ordinary Shares |
A - Award | 40 000 | 80 000 | 100,00 | ||||
2020-05-12 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Stock option (right to buy) |
M - Exercise | −33 479 | 0 | −100,00 | ||||
2020-05-12 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
S - Sale | X | −33 479 | 13 966 | −70,56 | 45,00 | −1 506 555 | 628 470 |
2020-05-12 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
M - Exercise | 33 479 | 47 445 | 239,72 | 4,96 | 166 056 | 235 327 | |
2020-03-13 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Stock option (right to buy) |
M - Exercise | −5 287 | 0 | −100,00 | ||||
2020-03-13 |
|
4 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
M - Exercise | 5 287 | 13 966 | 60,92 | 12,94 | 68 414 | 180 720 | |
2020-02-28 | 3 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
305 255 | ||||||||
2020-02-28 | 3 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
584 473 | ||||||||
2020-02-28 | 3 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
305 255 | ||||||||
2020-02-28 | 3 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
584 473 | ||||||||
2020-02-28 | 3 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
305 255 | ||||||||
2020-02-28 | 3 | HZNP |
Horizon Therapeutics Public Ltd Co
Ordinary Shares |
584 473 | ||||||||
2019-05-16 |
|
4 | SBBP |
Strongbridge Biopharma plc
Ordinary Shares |
A - Award | 40 000 | 40 000 | |||||
2019-03-01 |
|
4 | XERS |
XERIS PHARMACEUTICALS INC
Stock Option (right to buy) |
A - Award | 20 000 | 20 000 | |||||
2018-05-17 |
|
4 | SBBP |
Strongbridge Biopharma plc
Stock Options (Right to Buy) |
A - Award | 40 000 | 40 000 | |||||
2018-03-27 |
|
4 | HZNP |
Horizon Pharma plc
Restricted Stock Units |
M - Exercise | −19 250 | 19 250 | −50,00 | ||||
2018-03-27 |
|
4 | HZNP |
Horizon Pharma plc
Ordinary Shares |
F - Taxes | −8 528 | 212 341 | −3,86 | 13,86 | −118 198 | 2 943 046 | |
2018-03-27 |
|
4 | HZNP |
Horizon Pharma plc
Ordinary Shares |
M - Exercise | 19 250 | 220 869 | 9,55 | ||||
2018-01-03 |
|
4 | HZNP |
Horizon Pharma plc
Restricted Stock Units |
M - Exercise | −15 500 | 0 | −100,00 | ||||
2018-01-03 |
|
4 | HZNP |
Horizon Pharma plc
Ordinary Shares |
F - Taxes | −7 680 | 201 619 | −3,67 | 15,02 | −115 354 | 3 028 317 | |
2018-01-03 |
|
4 | HZNP |
Horizon Pharma plc
Ordinary Shares |
M - Exercise | 15 500 | 209 299 | 8,00 | ||||
2017-03-24 |
|
4 | HZNP |
Horizon Pharma plc
Restricted Stock Units |
M - Exercise | −19 250 | 38 500 | −33,33 | ||||
2017-03-24 |
|
4 | HZNP |
Horizon Pharma plc
Ordinary Shares |
F - Taxes | −8 798 | 192 350 | −4,37 | 14,56 | −128 099 | 2 800 616 | |
2017-03-24 |
|
4 | HZNP |
Horizon Pharma plc
Ordinary Shares |
M - Exercise | 19 250 | 201 148 | 10,58 | ||||
2017-01-04 |
|
4 | HZNP |
Horizon Pharma plc
Restricted Stock Units |
M - Exercise | −15 500 | 15 500 | −50,00 | ||||
2017-01-04 |
|
4 | HZNP |
Horizon Pharma plc
Restricted Stock Units |
M - Exercise | −11 250 | 0 | −100,00 | ||||
2017-01-04 |
|
4 | HZNP |
Horizon Pharma plc
Ordinary Shares |
F - Taxes | −12 602 | 181 898 | −6,48 | 16,18 | −203 900 | 2 943 110 | |
2017-01-04 |
|
4 | HZNP |
Horizon Pharma plc
Ordinary Shares |
M - Exercise | 26 750 | 194 500 | 15,95 | ||||
2016-12-19 |
|
4 | HZNP |
Horizon Pharma plc
Stock Option (Right to Buy) |
M - Exercise | −8 500 | 5 313 | −61,54 | ||||
2016-12-19 |
|
4 | HZNP |
Horizon Pharma plc
Ordinary Shares |
M - Exercise | 8 500 | 167 750 | 5,34 | 2,40 | 20 400 | 402 600 | |
2016-08-02 |
|
4 | HZNP |
Horizon Pharma plc
Ordinary Shares |
S - Sale | X | −2 900 | 159 250 | −1,79 | 20,00 | −58 000 | 3 185 000 |
2016-03-24 |
|
4 | HZNP |
Horizon Pharma plc
Restricted Stock Units |
M - Exercise | −19 250 | 57 750 | −25,00 | ||||
2016-03-24 |
|
4 | HZNP |
Horizon Pharma plc
Ordinary Shares |
F - Taxes | −8 798 | 160 100 | −5,21 | 16,32 | −143 583 | 2 612 832 | |
2016-03-24 |
|
4 | HZNP |
Horizon Pharma plc
Ordinary Shares |
M - Exercise | 19 250 | 168 898 | 12,86 | ||||
2016-02-29 |
|
4 | HZNP |
Horizon Pharma plc
Ordinary Shares |
S - Sale | X | −4 100 | 149 648 | −2,67 | 20,00 | −82 000 | 2 992 960 |
2016-01-05 |
|
4 | HZNP |
Horizon Pharma plc
Restricted Stock Units |
M - Exercise | −15 500 | 31 000 | −33,33 | ||||
2016-01-05 |
|
4 | HZNP |
Horizon Pharma plc
Restricted Stock Units |
M - Exercise | −11 250 | 11 250 | −50,00 | ||||
2016-01-05 |
|
4 | HZNP |
Horizon Pharma plc
Ordinary Shares |
F - Taxes | −8 576 | 153 748 | −5,28 | 21,67 | −185 842 | 3 331 719 | |
2016-01-05 |
|
4 | HZNP |
Horizon Pharma plc
Ordinary Shares |
M - Exercise | 26 750 | 162 324 | 19,73 | ||||
2015-12-16 |
|
4 | HZNP |
Horizon Pharma plc
Stock Option (Right to Buy) |
M - Exercise | −17 692 | 33 479 | −34,57 | ||||
2015-12-16 |
|
4 | HZNP |
Horizon Pharma plc
Stock Option (Right to Buy) |
M - Exercise | −12 750 | 13 813 | −48,00 | ||||
2015-12-16 |
|
4 | HZNP |
Horizon Pharma plc
Ordinary Shares |
M - Exercise | 17 692 | 135 574 | 15,01 | 4,96 | 87 752 | 672 447 | |
2015-12-16 |
|
4 | HZNP |
Horizon Pharma plc
Ordinary Shares |
M - Exercise | 12 750 | 117 882 | 12,13 | 2,40 | 30 600 | 282 917 | |
2015-12-10 |
|
4 | HZNP |
Horizon Pharma plc
Ordinary Shares |
S - Sale | X | 4 456 | 105 132 | 4,43 | 20,00 | 89 120 | 2 102 640 |
2015-12-10 |
|
4/A | HZNP |
Horizon Pharma plc
Restricted Stock Units |
M - Exercise | −8 208 | 0 | −100,00 | ||||
2015-12-10 |
|
4/A | HZNP |
Horizon Pharma plc
Ordinary Shares |
F - Taxes | −3 752 | 109 588 | −3,31 | 20,40 | −76 541 | 2 235 595 | |
2015-12-10 |
|
4/A | HZNP |
Horizon Pharma plc
Ordinary Shares |
M - Exercise | 8 208 | 113 340 | 7,81 | ||||
2015-12-09 |
|
4 | HZNP |
Horizon Pharma plc
Restricted Stock Units |
M - Exercise | −8 208 | 0 | −100,00 | ||||
2015-12-09 |
|
4 | HZNP |
Horizon Pharma plc
Ordinary Shares |
F - Taxes | −3 752 | 109 588 | −3,31 | 21,40 | −80 293 | 2 345 183 | |
2015-12-09 |
|
4 | HZNP |
Horizon Pharma plc
Ordinary Shares |
M - Exercise | 8 208 | 113 340 | 7,81 | ||||
2015-09-21 |
|
4 | HZNP |
Horizon Pharma plc
Ordinary Shares |
S - Sale | X | −7 750 | 105 132 | −6,87 | 31,78 | −246 295 | 3 341 095 |
2015-07-17 |
|
4 | HZNP |
Horizon Pharma plc
Stock Option (Right to Buy) |
M - Exercise | −2 450 | 51 171 | −4,57 | ||||
2015-07-17 |
|
4 | HZNP |
Horizon Pharma plc
Stock Option (Right to Buy) |
M - Exercise | −24 437 | 26 563 | −47,92 | ||||
2015-07-17 |
|
4 | HZNP |
Horizon Pharma plc
Ordinary Shares |
S - Sale | X | −2 450 | 112 882 | −2,12 | 35,55 | −87 098 | 4 012 955 |
2015-07-17 |
|
4 | HZNP |
Horizon Pharma plc
Ordinary Shares |
M - Exercise | 2 450 | 115 332 | 2,17 | 4,96 | 12 152 | 572 047 | |
2015-07-17 |
|
4 | HZNP |
Horizon Pharma plc
Ordinary Shares |
S - Sale | X | −24 437 | 112 882 | −17,80 | 35,55 | −868 735 | 4 012 955 |
2015-07-17 |
|
4 | HZNP |
Horizon Pharma plc
Ordinary Shares |
M - Exercise | 24 437 | 137 319 | 21,65 | 2,40 | 58 649 | 329 566 | |
2015-05-08 |
|
4 | HZNP |
Horizon Pharma plc
Performance Share Units (PSU) |
A - Award | 558 000 | 558 000 | |||||
2015-03-25 |
|
4 | HZNP |
Horizon Pharma plc
Performance Share Units (PSU) |
A - Award | 186 000 | 186 000 | |||||
2015-03-25 |
|
4 | HZNP |
Horizon Pharma plc
Restricted Stock Units |
A - Award | 77 000 | 77 000 | |||||
2015-03-25 |
|
4 | HZNP |
Horizon Pharma plc
Stock Option (Right to Buy) |
A - Award | 173 000 | 173 000 | |||||
2015-01-26 |
|
4 | HZNP |
Horizon Pharma plc
Restricted Stock Units |
M - Exercise | −8 208 | 8 208 | −50,00 | ||||
2015-01-26 |
|
4 | HZNP |
Horizon Pharma plc
Ordinary Shares |
F - Taxes | −2 656 | 84 336 | −3,05 | 12,99 | −34 501 | 1 095 525 | |
2015-01-26 |
|
4 | HZNP |
Horizon Pharma plc
Ordinary Shares |
M - Exercise | 8 208 | 86 992 | 10,42 | ||||
2015-01-26 |
|
4/A | HZNP |
Horizon Pharma plc
Restricted Stock Units |
M - Exercise | −11 250 | 33 750 | −25,00 | ||||
2015-01-26 |
|
4/A | HZNP |
Horizon Pharma plc
Common Stock |
M - Exercise | 11 250 | 102 596 | 12,32 | ||||
2015-01-06 |
|
4 | HZNP |
Horizon Pharma plc
Restricted stock units |
M - Exercise | −15 500 | 46 500 | −25,00 | ||||
2015-01-06 |
|
4 | HZNP |
Horizon Pharma plc
Restricted stock units |
M - Exercise | −11 250 | 22 500 | −33,33 | ||||
2015-01-06 |
|
4 | HZNP |
Horizon Pharma plc
Ordinary shares |
F - Taxes | −8 753 | 102 333 | −7,88 | 12,80 | −112 038 | 1 309 862 | |
2015-01-06 |
|
4 | HZNP |
Horizon Pharma plc
Ordinary shares |
M - Exercise | 26 750 | 111 086 | 31,72 | ||||
2014-11-20 |
|
4 | HZNP |
Horizon Pharma plc
Ordinary Shares |
S - Sale | −24 999 | 74 299 | −25,18 | 12,05 | −301 238 | 895 303 | |
2014-09-22 |
|
4 | HZNP |
Horizon Pharma plc
Restricted Stock Units |
D - Sale to Issuer | −62 000 | 0 | −100,00 | ||||
2014-09-22 |
|
4 | HZNP |
Horizon Pharma plc
Stock Option (Right to Buy) |
D - Sale to Issuer | −70 000 | 0 | −100,00 | ||||
2014-09-22 |
|
4 | HZNP |
Horizon Pharma plc
Restricted Stock Units |
D - Sale to Issuer | −33 750 | 0 | −100,00 | ||||
2014-09-22 |
|
4 | HZNP |
Horizon Pharma plc
Stock Option (Right to Buy) |
D - Sale to Issuer | −51 000 | 0 | −100,00 | ||||
2014-09-22 |
|
4 | HZNP |
Horizon Pharma plc
Restricted Stock Units |
D - Sale to Issuer | −16 416 | 0 | −100,00 | ||||
2014-09-22 |
|
4 | HZNP |
Horizon Pharma plc
Stock Option (Right to Buy) |
D - Sale to Issuer | −53 621 | 0 | −100,00 | ||||
2014-09-22 |
|
4 | HZNP |
Horizon Pharma plc
Stock Option (Right to Buy) |
D - Sale to Issuer | −42 295 | 0 | −100,00 | ||||
2014-09-22 |
|
4 | HZNP |
Horizon Pharma plc
Stock Option (Right to Buy) |
D - Sale to Issuer | −47 654 | 0 | −100,00 | ||||
2014-09-22 |
|
4 | HZNP |
Horizon Pharma plc
Stock Option (Right to Buy) |
D - Sale to Issuer | −46 335 | 0 | −100,00 | ||||
2014-09-22 |
|
4 | HZNP |
Horizon Pharma plc
Common Stock |
D - Sale to Issuer | −99 298 | 0 | −100,00 | ||||
2014-09-22 |
|
4 | HZNP |
Horizon Pharma plc
Restricted Stock Units |
A - Award | 62 000 | 62 000 | |||||
2014-09-22 |
|
4 | HZNP |
Horizon Pharma plc
Stock Option (Right to Buy) |
A - Award | 70 000 | 70 000 | |||||
2014-09-22 |
|
4 | HZNP |
Horizon Pharma plc
Restricted Stock Units |
A - Award | 33 750 | 33 750 | |||||
2014-09-22 |
|
4 | HZNP |
Horizon Pharma plc
Stock Option (Right to Buy) |
A - Award | 51 000 | 51 000 | |||||
2014-09-22 |
|
4 | HZNP |
Horizon Pharma plc
Restricted Stock Units |
A - Award | 16 416 | 16 416 | |||||
2014-09-22 |
|
4 | HZNP |
Horizon Pharma plc
Stock Option (Right to Buy) |
A - Award | 53 621 | 53 621 | |||||
2014-09-22 |
|
4 | HZNP |
Horizon Pharma plc
Stock Option (Right to Buy) |
A - Award | 42 295 | 42 295 | |||||
2014-09-22 |
|
4 | HZNP |
Horizon Pharma plc
Stock Option (Right to Buy) |
A - Award | 47 654 | 47 654 | |||||
2014-09-22 |
|
4 | HZNP |
Horizon Pharma plc
Stock Option (Right to Buy) |
A - Award | 46 335 | 46 335 | |||||
2014-09-22 |
|
4 | HZNP |
Horizon Pharma plc
Ordinary Shares |
A - Award | 99 298 | 99 298 | |||||
2014-05-21 |
|
4 | HZNP |
HORIZON PHARMA, INC.
Common stock |
S - Sale | X | −9 361 | 93 235 | −9,12 | 12,94 | −121 131 | 1 206 461 |
2014-01-10 |
|
4 | HZNP |
HORIZON PHARMA, INC.
Restricted stock units |
A - Award | 62 000 | 62 000 | |||||
2014-01-10 |
|
4 | HZNP |
HORIZON PHARMA, INC.
Employee stock options (right to buy) |
A - Award | 70 000 | 70 000 | |||||
2013-12-09 |
|
4 | HZNP |
HORIZON PHARMA, INC.
Restricted stock units |
M - Exercise | −8 208 | 16 416 | −33,33 | ||||
2013-12-09 |
|
4 | HZNP |
HORIZON PHARMA, INC.
Common Stock |
M - Exercise | 8 208 | 91 346 | 9,87 | ||||
2013-12-09 |
|
4 | HZNP |
HORIZON PHARMA, INC.
Common Stock |
A - Award | 18 037 | 83 138 | 27,71 | ||||
2013-01-03 |
|
4 | HZNP |
HORIZON PHARMA, INC.
Restricted stock units |
A - Award | 45 000 | 45 000 | |||||
2013-01-03 |
|
4 | HZNP |
HORIZON PHARMA, INC.
Employee stock options (right to buy) |
A - Award | 51 000 | 51 000 | |||||
2013-01-03 |
|
4 | HZNP |
HORIZON PHARMA, INC.
Common Stock |
S - Sale | X | 16 304 | 55 099 | 42,03 | 2,36 | 38 477 | 130 034 |
2012-12-12 |
|
4 | HZNP |
HORIZON PHARMA, INC.
Restricted stock units |
M - Exercise | −8 208 | 24 624 | −25,00 | ||||
2012-12-12 |
|
4 | HZNP |
HORIZON PHARMA, INC.
Common Stock |
M - Exercise | 8 208 | 71 403 | 12,99 | ||||
2012-07-27 |
|
4 | HZNP |
HORIZON PHARMA, INC.
Common Stock |
A - Award | 33 000 | 61 105 | 117,42 | ||||
2012-03-07 |
|
4 | HZNP |
HORIZON PHARMA, INC.
Common Stock |
A - Award | 22 000 | 22 000 |